Haematology patients infected with SARS-CoV-2, pretreated with eculizumab or siltuximab, develop oligosymptomatic disease
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
European journal of hospital pharmacy : science and practice - 29(2022), 6 vom: 04. Nov., Seite e8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Iluta, Sabina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
A3ULP0F556 |
|---|
| Anmerkungen: |
Date Completed 27.10.2022 Date Revised 09.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/ejhpharm-2021-002694 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32102561X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32102561X | ||
| 003 | DE-627 | ||
| 005 | 20231225174932.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/ejhpharm-2021-002694 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1070.xml |
| 035 | |a (DE-627)NLM32102561X | ||
| 035 | |a (NLM)33541912 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Iluta, Sabina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Haematology patients infected with SARS-CoV-2, pretreated with eculizumab or siltuximab, develop oligosymptomatic disease |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.10.2022 | ||
| 500 | |a Date Revised 09.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a allergy and immunology | |
| 650 | 4 | |a chemistry | |
| 650 | 4 | |a clinical | |
| 650 | 4 | |a clinical medicine | |
| 650 | 4 | |a hematology | |
| 650 | 4 | |a virology | |
| 650 | 7 | |a siltuximab |2 NLM | |
| 650 | 7 | |a T4H8FMA7IM |2 NLM | |
| 650 | 7 | |a eculizumab |2 NLM | |
| 650 | 7 | |a A3ULP0F556 |2 NLM | |
| 700 | 1 | |a Pasca, Sergiu |e verfasserin |4 aut | |
| 700 | 1 | |a Dima, Delia |e verfasserin |4 aut | |
| 700 | 1 | |a Mester, Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Urian, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Bojan, Anca |e verfasserin |4 aut | |
| 700 | 1 | |a Zdrenghea, Mihnea |e verfasserin |4 aut | |
| 700 | 1 | |a Trifa, Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Balacescu, Ovidiu |e verfasserin |4 aut | |
| 700 | 1 | |a Tomuleasa, Ciprian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of hospital pharmacy : science and practice |d 2012 |g 29(2022), 6 vom: 04. Nov., Seite e8 |w (DE-627)NLM225772213 |x 2047-9956 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2022 |g number:6 |g day:04 |g month:11 |g pages:e8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/ejhpharm-2021-002694 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2022 |e 6 |b 04 |c 11 |h e8 | ||